Robot-Assisted Percutaneous Coronary Intervention (PCI) Market Global Report 2026

The robot-assisted percutaneous coronary intervention (pci) market size has grown exponentially in recent years. It will grow from $0.03 billion in 2025 to $0.04 billion in 2026 at a compound annual growth rate (CAGR) of 26.4%. The growth in the historic period can be attributed to increasing prevalence of coronary artery disease, limitations in the precision of manual PCI procedures, growing use of catheter-based interventions, rising awareness of radiation exposure risks, and expansion of cardiac catheterization laboratories.

The robot-assisted percutaneous coronary intervention (pci) market size is expected to see exponential growth in the next few years. It will grow to $0.11 billion in 2030 at a compound annual growth rate (CAGR) of 26.0%. The growth in the forecast period can be attributed to advancements in robotic-assisted intervention technologies, increasing adoption of automation in cardiology, rising investment in digital healthcare infrastructure, growing demand for complex and high-risk PCI procedures, and supportive regulatory approvals for robotic systems. Major trends in the forecast period include rising adoption of minimally invasive cardiac procedures, growing focus on reducing radiation exposure for clinicians, increasing demand for precision and procedural accuracy, expansion of complex coronary intervention capabilities, and improved patient safety and clinical outcomes.

The increasing prevalence of cardiovascular diseases is expected to propel the growth of the robot-assisted percutaneous coronary intervention (PCI) market in the coming years. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart attacks, and stroke. The rise in cardiovascular diseases is largely associated with sedentary lifestyles, which contribute to obesity, hypertension, and poor heart health. Robot-assisted percutaneous coronary intervention (PCI) treats cardiovascular diseases by accurately reopening blocked or narrowed coronary arteries to restore blood flow to the heart while reducing procedural risks and radiation exposure, thereby improving patient outcomes. For instance, in December 2024, GOV.UK, a UK-based government agency, reported that in March 2024, nearly 2.24 million adults in England, representing about 4.4% of those aged 18 and over, had a GP-recorded diagnosis of CKD. This reflected an increase from 2.09 million cases in the previous year. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the robot-assisted percutaneous coronary intervention (PCI) market.

Major companies operating in the robot-assisted percutaneous coronary intervention (PCI) market are focusing on developing advanced robotic cardiology platforms to improve patient safety and streamline complex coronary interventions. A robotic cardiology platform is a high-tech system that assists cardiologists in performing accurate and controlled coronary procedures while enhancing precision, minimizing human error, and reducing radiation exposure for patients and medical staff. For instance, in May 2023, Robocath SAS, a France-based company specializing in robotic solutions for vascular interventions, launched the R-One+. This advanced robotic solution enables interventional cardiologists to perform coronary angioplasties (percutaneous coronary intervention, or PCI) by controlling devices through an integrated command unit located in the catheterization lab or control room. The R-One+ enhances precision in device manipulation, improves safety for both patients and medical staff by reducing radiation exposure, and provides more comfortable working conditions for operators. The launch was marked at the EuroPCR conference in Paris, where the platform demonstrated new capabilities designed to make PCI procedures easier and safer while protecting the cardiology team from radiation-induced injuries. This innovation reflects Robocath's commitment to improving cardiovascular disease treatments through smart robotic assistance.

In April 2024, Microbot Medical, a US-based developer of robotic endovascular systems and minimally invasive vascular solutions, partnered with Corewell Health. The partnership between Microbot Medical Inc. and Corewell Health aims to enable and advance remote telesurgery through the use of Microbot's LIBERTY Endovascular Robotic Surgical System. Corewell Health is a US-based healthcare company that provides robotic-assisted procedures and enhances patient care in cardiovascular interventions.

Major companies operating in the robot-assisted percutaneous coronary intervention (pci) market are Medtronic plc, Siemens Healthineers AG, Boston Scientific Corporation, Intuitive Surgical, BIOTRONIK SE & Co. KG, MicroPort Scientific Corporation, Biosensors International Group Ltd., OrbusNeich Medical Group Holdings Limited, Stereotaxis Inc., Perfint Healthcare, Robocath Inc., Meril Life Sciences Pvt. Ltd., Abbott Laboratories, Philips Healthcare, Terumo Corporation, Asahi Intecc, Catheter Precision, Cardiobot, Remedics, meerecompany Inc., AngioDynamics, Clear Surgical Inc., GE Healthcare, Canon Medical Systems, Asensus Surgical, Endovascular Robotics.

North America was the largest region in the robot-assisted percutaneous coronary intervention (PCI) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the robot-assisted percutaneous coronary intervention (pci) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the robot-assisted percutaneous coronary intervention (pci) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 1-3 business days.